Liminatus Pharma, Inc. closed a best-efforts public offering raising approximately $4,000,000 in gross proceeds, consisting of common stock (or pre-funded warrants) and accompanying warrants priced at $0.29 per share. The warrants are exercisable immediately at $0.29 per share and expire five years from issuance.
Proceeds are intended for working capital, general corporate purposes, and advancement of the company’s immuno-oncology development programs.
Maxim Group LLC served as sole placement agent, with Lucosky Brookman LLP acting as placement agent counsel.
